Loading...
Key Finding
Ribociclib + Fulvestrant maintains Quality of Life (QoL) while prolonging progression-free survival compared to Placebo. Time to deterioration (TTD) generally favored the Ribociclib arm across Global Health, Physical Functioning, and Pain metrics.
Study Design & Arms
Randomized, double-blind, placebo-controlled Phase III trial (2:1 ratio)
Baseline Global Health Status
Metric: M01 (Score 0-100, Higher is Better). Mean ± SD.
Time to Deterioration (TTD): Global Health Status
Metric: M02. Median Months (Higher is Better). HR = 0.81 [0.62–1.1]
Time to Deterioration: Physical Functioning
Metric: M03. Mean Months (Higher is Better). HR = 0.82 [0.61–1.10]
Time to Deterioration: Pain Severity
Metric: M04. Median Months (Higher is Better). HR = 0.77 [0.57–1.05]
Change in Pain Scores (8 Weeks)
Metric: M05. Score Change (Lower is Better/More Reduction).
Appendix
Study Limits
Raw Data
| Metric | Group | Value | Provenance |
|---|